Cyclin E expression and early cervical neoplasia in ThinPrep specimens. A feasibility study.

Area of Science:

• Gynecologic Pathology
• Molecular Diagnostics
• Cervical Cancer Screening

Background:

• Cervical neoplasia poses a significant health concern, necessitating accurate early detection methods.
• Human papillomavirus (HPV) infection is a primary cause of cervical preneoplastic lesions.
• Current screening methods may require adjunct markers for improved diagnostic accuracy.

Purpose of the Study:

• To evaluate cyclin E as a potential biomarker for early cervical neoplasia.
• To assess the correlation between cyclin E expression and HPV infection in ThinPrep specimens.
• To determine the utility of cyclin E in identifying preneoplastic changes in the cervix.

Main Methods:

• Immunocytochemical staining of ThinPrep specimens using cyclin E and HPV antibodies.
• Analysis of specimens diagnosed with HPV infection, atypical squamous cells of undetermined significance (ASCUS), and normal/benign cellular changes (WNL/BCC).
• Scoring of cyclin E expression by two pathologists and correlation with cytologic diagnoses.

Main Results:

• Cyclin E positivity was observed in 100% of HPV-diagnosed cases, correlating with HPV antibody positivity.
• Four percent of WNL/BCC cases showed cyclin E positivity, with two also positive for HPV antibody.
• Seventy-three percent of ASCUS cases were positive for both cyclin E and HPV antibodies.

Conclusions:

• Cyclin E expression is strongly associated with HPV infection and associated morphologic changes in ThinPrep specimens.
• Cyclin E may function as a surrogate marker for HPV infection.
• The findings suggest cyclin E's potential role in identifying early cervical preneoplastic lesions.